TrialInternational journal of hematology2018

Efficacy and safety of switching to nilotinib in patients with CML-CP in major molecular response to imatinib: results of a multicenter phase II trial (NILSw trial).

Jun Ishikawa et al.PubMed ↗Publisher ↗

No numbers read from the abstract.